



RECEIVED

MAY 03 2002

#118B
DIA
5/7/02

DOCKET NO.: PHRM-0303 (6225)

PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Gurney *et al.***

Serial No.: **09/767,088**

Group Art Unit: **1632**

Filed: **January 22, 2001**

Examiner: **A.-M. Baker**

For: **TRANSGENIC MOUSE MODEL OF
HUMAN NEURODEGENERATIVE DISEASE**

EXPRESS MAIL LABEL NO: EV 058073094 US
DATE OF DEPOSIT: April 25, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

RESPONSE AND AMENDMENT

This amendment is in response to the Office Communication mailed April 1, 2002. Applicants respectfully request that the application be amended as follows.

IN THE SPECIFICATION

At page 5, replace paragraph [0023] with the following replacement paragraph:

B.1
Tau protein microtubule binding domains, which contain the core microtubule binding domain motif proline-glycine-glycine-glycine (PGGG) [SEQ ID NO:16], are designated R1, R2, R3, and R4, and are encoded by exons 9, 10, 11, and 12, respectively. Exon 10, which encodes amino acid residues 275 through 305, is alternatively utilized (present in three of the six isoforms), such that the R2 microtubule binding domain is present only in tau isoforms containing four repeats. Thus, the isoforms range in size from 352 amino acid residues (with no amino-terminal inserts and three microtubule binding domains) to 441 amino acid residues (with